Verve Therapeutics, Inc. (NASDAQ:VERV) CFO Allison Dorval Sells 3,350 Shares

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) CFO Allison Dorval sold 3,350 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total transaction of $13,902.50. Following the transaction, the chief financial officer now directly owns 13,280 shares of the company's stock, valued at approximately $55,112. This represents a 20.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Verve Therapeutics Stock Performance

NASDAQ:VERV traded down $0.37 during mid-day trading on Tuesday, reaching $2.97. The stock had a trading volume of 2,340,162 shares, compared to its average volume of 1,441,172. The stock has a market capitalization of $263.72 million, a P/E ratio of -1.21 and a beta of 1.86. The firm has a 50 day moving average price of $6.34 and a two-hundred day moving average price of $5.98. Verve Therapeutics, Inc. has a one year low of $2.91 and a one year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Research analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Institutional Trading of Verve Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL lifted its stake in shares of Verve Therapeutics by 962.2% in the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock valued at $38,939,000 after acquiring an additional 6,254,050 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Verve Therapeutics in the 4th quarter worth approximately $7,863,000. Schonfeld Strategic Advisors LLC lifted its position in Verve Therapeutics by 57.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock valued at $21,372,000 after purchasing an additional 1,382,176 shares during the last quarter. State Street Corp boosted its stake in shares of Verve Therapeutics by 27.0% during the third quarter. State Street Corp now owns 4,253,217 shares of the company's stock valued at $20,586,000 after purchasing an additional 903,809 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Verve Therapeutics by 72.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company's stock valued at $7,547,000 after purchasing an additional 653,578 shares during the period. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on VERV shares. Guggenheim reissued a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Finally, Royal Bank of Canada lowered their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $20.67.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.